Tego Science, Inc.
Develops and commercializes cell therapies for regenerative medicine.
191420 | KO
Overview
Corporate Details
- ISIN(s):
- KR7191420009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
- Website:
- http://www.tegoscience.com/
- Sector:
- Manufacturing
Description
Tego Science, Inc. is a biopharmaceutical company specializing in the development and commercialization of cell therapies for regenerative medicine. The company leverages proprietary, advanced cell culture technology for the mass production of human epithelial cells. Its portfolio of approved products includes Holoderm®, an autologous cultured epidermis for severe burns; Kaloderm®, an allogeneic cell therapy for burns and diabetic foot ulcers; and Rosmir®, an autologous fibroblast treatment for wrinkles. In addition to its therapeutic products, Tego Science provides Neoderm®, a 3D cultured skin model used as an alternative to animal testing, and offers CDMO services. The company's clinical pipeline features TPX-115, a first-in-class allogeneic fibroblast-based therapy for treating rotator cuff tears, currently in late-stage clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-08-14 00:00 |
반기보고서 (2020.06)
|
Korean | 781.1 KB | ||
| 2020-08-06 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 17.9 KB | ||
| 2020-07-20 00:00 |
기업설명회(IR)개최
|
Korean | 7.4 KB | ||
| 2020-07-03 00:00 |
기업설명회(IR)개최
|
Korean | 7.4 KB | ||
| 2020-06-19 00:00 |
신탁계약에의한취득상황보고서
|
Korean | 22.1 KB | ||
| 2020-06-03 00:00 |
[첨부추가]기업설명회(IR)개최
|
Korean | 7.4 KB | ||
| 2020-05-12 00:00 |
분기보고서 (2020.03)
|
Korean | 722.4 KB | ||
| 2020-04-27 00:00 |
기타경영사항(자율공시)(보건복지부 국책과제 선정)
|
Korean | 6.5 KB | ||
| 2020-04-07 00:00 |
기타경영사항(특허권취득)(자율공시)(켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물(국내특허))
|
Korean | 5.0 KB | ||
| 2020-04-02 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.5 KB | ||
| 2020-04-02 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 121.0 KB | ||
| 2020-03-30 00:00 |
사업보고서 (2019.12)
|
Korean | 1.0 MB | ||
| 2020-03-30 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 6.3 KB | ||
| 2020-03-27 00:00 |
정기주주총회결과
|
Korean | 21.6 KB | ||
| 2020-03-25 00:00 |
투자판단관련주요경영사항(회전근개파열 세포치료제 'TPX-115' 제1/2상 임상시험계획 승인)
|
Korean | 10.6 KB |
Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tego Science, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
